Lanzor (Lansoprazole)

Lansoprazole selectively and irreversibly blocks the H+/K+ ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By inhibiting this final step of acid production, it markedly lowers both basal and stimulated gastric acid output, increasing gastric pH and allowing damaged mucosa to heal.

The dosage of Lanzor is determined by the prescribing clinician based on the specific indication, patient age, renal function and treatment duration. Healthcare professionals select the appropriate strength and dosing schedule, which may range from once‑daily to twice‑daily administration, and adjust as needed during therapy.

Safety data for lansoprazole in pregnancy and lactation are limited. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians are advised to evaluate each case individually and consider alternative therapies when appropriate.

To place an order, visit the product page for Lanzor on the GNH India website (gnhindia.com), submit an enquiry with the required quantity, and provide institutional or trade credentials. GNH India’s procurement team will verify the information, then respond with pricing, availability, shipping terms and any necessary import documentation.

Lanzor (lansoprazole) belongs to the proton pump inhibitor class, which provides more potent and longer‑lasting acid suppression than H2‑receptor antagonists such as ranitidine. Compared with other PPIs, lansoprazole has a similar efficacy profile but may differ in pharmacokinetic properties, drug‑interaction potential and dosing convenience.

Lanzor tablets should be stored at room temperature, below 25 °C, in the original blister pack or container to protect them from moisture and light. Keep the medication out of reach of children and avoid storing in humid environments such as bathrooms.

Lanzor is taken orally, usually swallowed whole with a glass of water. It can be taken with or without food, but consistency in timing relative to meals helps maintain steady drug levels. Patients should follow the prescribing clinician’s instructions regarding frequency and duration of therapy.

Although uncommon, serious adverse events linked to lansoprazole include severe allergic reactions (anaphylaxis), Clostridioides difficile‑associated colitis, hypomagnesemia leading to muscle cramps or cardiac arrhythmias, and increased risk of bone fractures with long‑term use. Patients should seek immediate medical attention if they experience symptoms such as rash, severe diarrhea, muscle weakness or unexplained falls.

Lanzor is contraindicated in individuals with known hypersensitivity to lansoprazole or any component of the formulation. Caution is also advised for patients with severe hepatic impairment, those taking medications that require an acidic environment for absorption, and patients with a history of osteoporosis or fracture risk when considering prolonged therapy.